<!doctype html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width,initial-scale=1" />
  <title>Cape Porpoise Clinical Consulting</title>
  <meta name="description" content="Clinical and regulatory consulting for early-stage biotech. Strategy to execution." />
  <link rel="preconnect" href="https://fonts.googleapis.com">
  <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
  <link href="https://fonts.googleapis.com/css2?family=Libre+Baskerville:ital,wght@0,400;0,700;1,400&family=DM+Sans:opsz,wght@9..40,400;9..40,500;9..40,600&display=swap" rel="stylesheet">

  <style>
    :root {
      --ink: #0e1219;
      --paper: #f7f4ef;
      --muted: #6b6660;
      --accent: #1a3a5c;
      --rule: #d4cfc7;
      --serif: 'Libre Baskerville', Georgia, serif;
      --sans: 'DM Sans', system-ui, sans-serif;
    }

    *, *::before, *::after { box-sizing: border-box; margin: 0; padding: 0; }
    html { scroll-behavior: smooth; }

    body {
      font-family: var(--sans);
      background: var(--paper);
      color: var(--ink);
      line-height: 1.6;
    }

nav {
  position: sticky;
  top: 0;
  z-index: 100;
  background: rgba(247,244,239,.95);
  backdrop-filter: blur(10px);
  border-bottom: 1px solid var(--rule);
  padding: 0 48px;
  display: flex;
  justify-content: space-between;
  align-items: center;
  height: 200px;
}

    .brand {
      display: flex;
      align-items: center;
      text-decoration: none;
      color: var(--ink);
    }

    .brand-logo {
      height: 200px;
      width: auto;
      display: block;
    }

    .nav-links { display: flex; gap: 24px; list-style: none; }

    .nav-links a {
      font-size: 12px;
      font-weight: 600;
      letter-spacing: .07em;
      text-transform: uppercase;
      color: var(--muted);
      text-decoration: none;
      transition: color .15s;
    }

    .nav-links a:hover { color: var(--ink); }

    .hero {
      min-height: 84vh;
      display: flex;
      flex-direction: column;
      justify-content: flex-end;
      padding: 72px 48px;
      border-bottom: 1px solid var(--rule);
    }

    .eyebrow {
      font-size: 11px;
      font-weight: 600;
      letter-spacing: .18em;
      text-transform: uppercase;
      color: var(--muted);
      margin-bottom: 22px;
      display: flex;
      align-items: center;
      gap: 12px;
      opacity: 0;
      animation: up .6s ease .1s forwards;
    }

    .eyebrow::before {
      content: '';
      width: 24px;
      height: 1px;
      background: var(--muted);
      flex-shrink: 0;
    }

    h1 {
      font-family: var(--serif);
      font-size: clamp(34px, 5.5vw, 72px);
      line-height: 1.08;
      letter-spacing: -.02em;
      max-width: 820px;
      margin-bottom: 32px;
      opacity: 0;
      animation: up .7s ease .2s forwards;
    }

    h1 em { font-style: italic; color: var(--accent); }

    .cta-row {
      display: flex;
      gap: 14px;
      align-items: center;
      opacity: 0;
      animation: up .7s ease .33s forwards;
    }

    .btn {
      background: var(--accent);
      color: #fff;
      padding: 13px 24px;
      border-radius: 3px;
      text-decoration: none;
      font-size: 13px;
      font-weight: 600;
      letter-spacing: .04em;
      transition: opacity .15s;
    }

    .btn:hover { opacity: .85; }

    section { border-bottom: 1px solid var(--rule); }

    .row {
      max-width: 1060px;
      margin: 0 auto;
      padding: 72px 48px;
      display: grid;
      grid-template-columns: 180px 1fr;
      gap: 52px;
    }

    .label {
      font-size: 10.5px;
      font-weight: 700;
      letter-spacing: .18em;
      text-transform: uppercase;
      color: var(--muted);
      padding-top: 4px;
    }

    .body-lg {
      font-size: 18px;
      line-height: 1.7;
      max-width: 660px;
      margin-bottom: 20px;
    }

    .body-lg:last-child { margin-bottom: 0; }

    /* TAG GROUPS */
    .tag-group { margin-bottom: 28px; }
    .tag-group:last-child { margin-bottom: 0; }

    .tag-group-title {
      font-size: 10.5px;
      font-weight: 700;
      letter-spacing: .16em;
      text-transform: uppercase;
      color: var(--muted);
      margin-bottom: 10px;
    }

    .tags { display: flex; flex-wrap: wrap; gap: 7px; }

    .tag {
      font-size: 13px;
      color: var(--ink);
      border: 1px solid var(--rule);
      padding: 5px 13px;
      border-radius: 999px;
      background: #fff;
    }

    /* STAT GRIDS */
    .stat-grid {
      display: grid;
      gap: 1px;
      background: var(--rule);
      border: 1px solid var(--rule);
      border-radius: 5px;
      overflow: hidden;
    }

    .stat-grid-4 { grid-template-columns: repeat(4, 1fr); }
    .stat-grid-3 { grid-template-columns: repeat(3, 1fr); }

    .stat-cell {
      background: var(--paper);
      padding: 24px 20px;
    }

    .stat-cell strong {
      display: block;
      font-family: var(--serif);
      font-size: 36px;
      color: var(--accent);
      line-height: 1;
      margin-bottom: 8px;
    }

    .stat-cell span {
      font-size: 12.5px;
      color: var(--muted);
      line-height: 1.45;
    }

    /* CHART */
    .chart-label {
      font-size: 10.5px;
      font-weight: 700;
      letter-spacing: .16em;
      text-transform: uppercase;
      color: var(--muted);
      margin-bottom: 14px;
      margin-top: 36px;
    }

    .chart-outer {
      border: 1px solid var(--rule);
      border-radius: 5px;
      padding: 24px 24px 0;
      background: var(--paper);
    }

    .bars {
      display: flex;
      align-items: flex-end;
      gap: 10px;
      height: 110px;
      border-bottom: 1px solid var(--rule);
    }

    .bar-col { flex: 1; }

    .bar-fill {
      width: 100%;
      background: var(--accent);
      border-radius: 2px 2px 0 0;
    }

    .bar-labels {
      display: flex;
      gap: 10px;
      padding: 10px 0 16px;
    }

    .bar-lbl {
      flex: 1;
      text-align: center;
      font-size: 11px;
      color: var(--muted);
      line-height: 1.5;
    }

    .bar-lbl strong {
      display: block;
      font-size: 12px;
      color: var(--ink);
      font-weight: 600;
    }

    .chart-source {
      font-size: 11.5px;
      color: var(--muted);
      line-height: 1.55;
      padding: 12px 0 20px;
      border-top: 1px solid var(--rule);
      margin-top: 4px;
    }

    /* SERVICES */
    .svc-cols {
      display: grid;
      grid-template-columns: 1fr 1fr;
      gap: 1px;
      background: var(--rule);
      border: 1px solid var(--rule);
      border-radius: 5px;
      overflow: hidden;
      width: 100%;
    }

    .svc-col { background: var(--paper); padding: 32px 28px; }

    .svc-col-label {
      font-size: 10px;
      font-weight: 700;
      letter-spacing: .17em;
      text-transform: uppercase;
      color: var(--muted);
      margin-bottom: 5px;
    }

    .svc-col-title {
      font-family: var(--serif);
      font-size: 19px;
      line-height: 1.2;
      margin-bottom: 7px;
    }

    .svc-desc {
      font-size: 13.5px;
      color: var(--muted);
      line-height: 1.55;
      margin-bottom: 20px;
      padding-bottom: 20px;
      border-bottom: 1px solid var(--rule);
    }

    .svc-list { list-style: none; display: flex; flex-direction: column; gap: 10px; }

    .svc-list li {
      font-size: 14px;
      color: var(--muted);
      line-height: 1.45;
      padding-left: 14px;
      position: relative;
    }

    .svc-list li::before {
      content: '';
      position: absolute;
      left: 0;
      top: 9px;
      width: 5px;
      height: 1px;
      background: var(--rule);
    }

    /* ABOUT */
    .about-body p {
      font-size: 15.5px;
      line-height: 1.78;
      color: var(--muted);
      margin-bottom: 16px;
      max-width: 660px;
    }

    .about-body p:last-child { margin-bottom: 0; }
    .about-body strong { color: var(--ink); font-weight: 600; }

    .about-body a {
      color: var(--accent);
      text-decoration: none;
      border-bottom: 1px solid var(--rule);
      transition: border-color .15s;
    }

    .about-body a:hover { border-color: var(--accent); }

    /* CONTACT */
    .contact-tag {
      font-family: var(--serif);
      font-size: 25px;
      line-height: 1.3;
      margin-bottom: 28px;
      max-width: 440px;
    }

    .contact-links { display: flex; flex-direction: column; margin-bottom: 24px; }

    .contact-link {
      display: flex;
      justify-content: space-between;
      align-items: center;
      font-size: 16px;
      font-weight: 500;
      color: var(--accent);
      text-decoration: none;
      padding: 13px 0;
      border-bottom: 1px solid var(--rule);
      transition: color .15s;
    }

    .contact-link:first-child { border-top: 1px solid var(--rule); }
    .contact-link:hover { color: #2d5f8a; }

    .arr { transition: transform .15s; }
    .contact-link:hover .arr { transform: translateX(4px); }

    .contact-note { font-size: 13px; color: var(--muted); line-height: 1.65; max-width: 380px; }

footer {
  padding: 0 48px 48px;
  display: flex;
  flex-direction: column;
  align-items: center;
  gap: 0;
  border-top: 1px solid var(--rule);
}

    .footer-logo {
      height: 160px;
      width: auto;
      display: block;
      margin: 40px auto 20px;
    }

    .footer-meta {
      width: 100%;
      display: flex;
      justify-content: space-between;
      flex-wrap: wrap;
      gap: 8px;
    }

    footer p { font-size: 12px; color: var(--muted); }

    @keyframes up {
      from { opacity: 0; transform: translateY(20px); }
      to   { opacity: 1; transform: translateY(0); }
    }

    @media (max-width: 780px) {
       nav { padding: 0 20px; height: 120px; }
      .brand-logo { height: 100px; }
      .nav-links { display: none; }
      .hero { padding: 56px 20px; min-height: 68vh; }
      .row { grid-template-columns: 1fr; gap: 14px; padding: 52px 20px; }
      .svc-cols { grid-template-columns: 1fr; }
      .stat-grid-4 { grid-template-columns: 1fr 1fr; }
      .stat-grid-3 { grid-template-columns: 1fr 1fr; }
      footer { padding: 0 20px 24px; }
      .footer-logo { height: 100px; }
    }
  </style>
</head>

<body>

  <nav>
    <a class="brand" href="#top">
      <img class="brand-logo" src="CPCC_logo.png" alt="Cape Porpoise Clinical Consulting" />
    </a>
    <ul class="nav-links">
      <li><a href="#focus">Focus</a></li>
      <li><a href="#expertise">Expertise</a></li>
      <li><a href="#about">About</a></li>
      <li><a href="#industrytrends">Industry Trends</a></li>
      <li><a href="#contact">Contact</a></li>
    </ul>
  </nav>

  <div class="hero" id="top">
    <div class="eyebrow">Cape Porpoise Clinical Consulting &middot; Cambridge, MA</div>
    <h1>Helping lean biotech<br>chart a course to <em>meaningful clinical inflection points.</em></h1>
    <div class="cta-row">
      <a class="btn" href="#contact">Get in touch</a>
    </div>
  </div>

  <!-- FOCUS + SERVICES -->
  <section id="focus">
    <div class="row">
      <div class="label">What we do</div>
      <div>
        <p class="body-lg">CPCC works exclusively with <strong>early clinical-stage biotech companies</strong> to efficiently navigate the path from candidate selection and confirmation to meaningful clinical inflection points: the data, regulatory decisions, and milestones that unlock program advancement and company growth.</p>
        <p class="body-lg">Whether you need a senior thought partner to support interactions with inbounds, the board, or regulatory authorities, or just need someone to build the clinical and regulatory infrastructure and get the work done, CPCC covers the full range. High-level development strategy through hands-on execution and submission-ready deliverables.</p>
        <p class="body-lg" style="margin-bottom:36px;">CPCC embeds directly with your team — large or small. For lean startups without a full clinical function, Amanda can serve as a fractional head of clinical development and regulatory affairs, owning strategy and execution end to end. For larger teams, she plugs in to lead specific workstreams, fill senior gaps, or provide surge capacity at critical moments.</p>

        <div class="svc-cols">
          <div class="svc-col">
            <div class="svc-col-label">Strategic</div>
            <div class="svc-col-title">Advisory and Consulting</div>
            <p class="svc-desc">Senior judgment at the table for investor and regulatory interactions and program-level planning.</p>
            <ul class="svc-list">
              <li>Clinical and regulatory development strategy</li>
              <li>Trial design and endpoint selection</li>
              <li>FDA meeting preparation and participation</li>
              <li>Investor and board-level scientific and operational advisory</li>
              <li>Clinical and regulatory risk assessment</li>
              <li>Partnership and due diligence support</li>
            </ul>
          </div>
          <div class="svc-col">
            <div class="svc-col-label">Execution</div>
            <div class="svc-col-title">Clinical and Regulatory Work</div>
            <p class="svc-desc">Submission-ready deliverables built directly. First drafts that hold up through review.</p>
            <ul class="svc-list">
              <li>Medical writing: IBs, protocols, ICFs, CSRs</li>
              <li>IND and CTA preparation and submission</li>
              <li>Regulatory correspondence and agency responses</li>
              <li>Clinical trial project management</li>
              <li>Data management and pharmacovigilance oversight</li>
              <li>Vendor oversight and operational problem-solving</li>
              <li>QC and narrative coherence review</li>
            </ul>
          </div>
        </div>
      </div>
    </div>
  </section>

  <!-- EXPERTISE + TRACK RECORD COMBINED -->
  <section id="expertise">
    <div class="row">
      <div class="label">Expertise</div>
      <div>
        <div class="tag-group">
          <div class="tag-group-title">Therapeutic Areas</div>
          <div class="tags">
            <span class="tag">Cardiovascular</span>
            <span class="tag">Neurology</span>
            <span class="tag">Rare Disease</span>
            <span class="tag">Oncology</span>
            <span class="tag">Respiratory</span>
            <span class="tag">Microbiome / GI</span>
          </div>
        </div>
        <div class="tag-group">
          <div class="tag-group-title">Modalities</div>
          <div class="tags">
            <span class="tag">Antibody-Protein Fusions</span>
            <span class="tag">Antibody-Drug Conjugates</span>
            <span class="tag">Bispecific Antibodies</span>
            <span class="tag">RNAi / siRNA</span>
            <span class="tag">Small Molecules</span>
            <span class="tag">Combination Drug / Device Products</span>
            <span class="tag">Inhaled Drug Delivery</span>
            <span class="tag">Microbiome Therapeutics</span>
          </div>
        </div>
        <div class="tag-group">
          <div class="tag-group-title">Functional Areas</div>
          <div class="tags">
            <span class="tag">Regulatory Affairs</span>
            <span class="tag">Medical Writing</span>
            <span class="tag">Clinical Operations</span>
            <span class="tag">Data Management</span>
            <span class="tag">Pharmacovigilance</span>
            <span class="tag">Program Management</span>
            <span class="tag">Vendor Selection &amp; Oversight</span>
          </div>
        </div>
        <div class="tag-group">
          <div class="tag-group-title">Companies</div>
          <div class="tags">
            <span class="tag">Salubris Biotherapeutics</span>
            <span class="tag">Acorda Therapeutics</span>
            <span class="tag">Dicerna Pharmaceuticals</span>
            <span class="tag">Nocion Therapeutics</span>
            <span class="tag">Elevian</span>
            <span class="tag">Finch Therapeutics</span>
            <span class="tag">Pharmica Consulting</span>
          </div>
        </div>

        <!-- TRACK RECORD folded in -->
        <div style="margin-top:52px;">
          <div style="font-size:10.5px;font-weight:700;letter-spacing:.18em;text-transform:uppercase;color:var(--muted);margin-bottom:20px;">Track Record</div>
          <p class="body-lg" style="font-size:15.5px;margin-bottom:28px;">Over 18 years inside small and midsize biotech across Boston and Cambridge, Amanda has guided programs from first-in-human through FDA approval, exits, and partnerships. Two FDA-approved drugs. Twelve INDs. Three NDA contributions. A career built entirely in small biotech — working across every function, and knowing how to move programs forward with lean teams and limited resources.</p>
          <div class="stat-grid stat-grid-4">
            <div class="stat-cell"><strong>18+</strong><span>Years in clinical biotech leadership</span></div>
            <div class="stat-cell"><strong>12+</strong><span>INDs filed</span></div>
            <div class="stat-cell"><strong>3</strong><span>NDA contributions</span></div>
            <div class="stat-cell"><strong>2</strong><span>FDA-approved therapies</span></div>
          </div>
        </div>
      </div>
    </div>
  </section>

  <!-- ABOUT -->
  <section id="about">
    <div class="row">
      <div class="label">About</div>
      <div class="about-body">
        <p>CPCC is led by <strong>Amanda McEwen</strong> — <a href="https://www.linkedin.com/in/amandamariegentilemcewen/" target="_blank" rel="noopener">LinkedIn</a> — SVP of Clinical Development at Salubris Biotherapeutics, where she leads the JK07 program, a first-in-class ErbB4 agonist in Phase 2b for heart failure.</p>
        <p>Amanda has spent her entire career inside small biotech, where the boundaries between clinical development, regulatory affairs, operations, data management, and pharmacovigilance are rarely as clean as an org chart suggests. That breadth — built from years of doing the work across functions, not just overseeing it — is what CPCC brings to client teams. She embeds fluidly with both small founding teams that need a full clinical function built out, and larger organizations that need senior capacity on a specific workstream or at a critical juncture.</p>
        <p>Her career highlights include key contributions to two FDA-approved therapies: <strong>Inbrija</strong>, for Parkinson's disease, and <strong>Rivfloza</strong>, for a rare genetic liver disease. She is especially passionate about early-phase development and has led several initiatives spanning preclinical research through clinical proof of concept.</p>
        <p>Beyond her industry role, Amanda is an <strong>Executive Fellow at Harvard Business School</strong> and adjunct faculty in <strong>Northeastern University's MS in Regulatory Affairs</strong> program. She is also a current PhD candidate in Business Analytics at Bentley University. She earned her BA from the College of the Holy Cross and a Master of Research Methods in Psychology from the University of York in England.</p>
      </div>
    </div>
  </section>

  <!-- INDUSTRY TRENDS -->
<section id="industrytrends">
  <div class="row">
    <div class="label">Clinical Data Fuels M&amp;A</div>
    <div>
      <p class="body-lg">The market has fundamentally reoriented around clinical data. Pharma is spending more than ever on licensing and acquisitions, but concentrating it across <strong>fewer, higher-conviction deals</strong> — and those deals are increasingly targeting companies with clinical-stage assets and de-risked data packages. The inflection point is the value inflection point.</p>

      <div class="stat-grid stat-grid-3" style="margin-top:36px;margin-bottom:36px;">
        <div class="stat-cell">
          <strong>83%</strong>
          <span>Of biopharma M&amp;A transactions in H1 2023 focused on assets in Phase 3 or already on market — up from 59% in 2019. Source: IQVIA</span>
        </div>
        <div class="stat-cell">
          <strong>4x</strong>
          <span>Drop in preclinical-stage IPO value in 2024 vs 2023 — public investors shifting hard toward clinical-stage assets. Source: GlobalData</span>
        </div>
        <div class="stat-cell">
          <strong>$228B</strong>
          <span>Biopharma M&amp;A in 2025 — up 73% from 2024 — driven by patent cliffs and abundance of clinical-stage targets with de-risked data. Source: Vision Lifesciences</span>
        </div>
      </div>

      <!-- Stacked bar chart: clinical vs preclinical/early deal share -->
      <div class="chart-label">Share of biopharma M&amp;A deals by asset stage &mdash; IQVIA</div>
      <div class="chart-outer">

        <!-- Y-axis labels + bars -->
        <div style="display:flex;gap:12px;align-items:flex-end;">

          <!-- Y axis -->
          <div style="display:flex;flex-direction:column;justify-content:space-between;height:140px;padding-bottom:0;flex-shrink:0;">
            <span style="font-size:10px;color:var(--muted);">100%</span>
            <span style="font-size:10px;color:var(--muted);">75%</span>
            <span style="font-size:10px;color:var(--muted);">50%</span>
            <span style="font-size:10px;color:var(--muted);">25%</span>
            <span style="font-size:10px;color:var(--muted);">0%</span>
          </div>

          <!-- Bars -->
          <div style="flex:1;display:flex;align-items:flex-end;gap:10px;height:140px;border-bottom:1px solid var(--rule);border-left:1px solid var(--rule);">

            <!-- 2019: 59% de-risked (Ph3+commercial), 41% early -->
            <div style="flex:1;display:flex;flex-direction:column;height:100%;">
              <div style="flex:1;background:var(--rule);border-radius:2px 2px 0 0;"></div><!-- early: 41% -->
              <div style="height:59%;background:var(--accent);opacity:.9;"></div><!-- de-risked: 59% -->
            </div>

            <!-- 2020: ~62% de-risked -->
            <div style="flex:1;display:flex;flex-direction:column;height:100%;">
              <div style="flex:1;background:var(--rule);border-radius:2px 2px 0 0;"></div>
              <div style="height:62%;background:var(--accent);opacity:.9;"></div>
            </div>

            <!-- 2021: 29% commercial (lower de-risked share, more platform deals) ~55% -->
            <div style="flex:1;display:flex;flex-direction:column;height:100%;">
              <div style="flex:1;background:var(--rule);border-radius:2px 2px 0 0;"></div>
              <div style="height:55%;background:var(--accent);opacity:.9;"></div>
            </div>

            <!-- 2022: step up, 45% commercial alone, ~70% de-risked total -->
            <div style="flex:1;display:flex;flex-direction:column;height:100%;">
              <div style="flex:1;background:var(--rule);border-radius:2px 2px 0 0;"></div>
              <div style="height:70%;background:var(--accent);opacity:.9;"></div>
            </div>

            <!-- H1 2023: 83% de-risked (Ph3+commercial) -->
            <div style="flex:1;display:flex;flex-direction:column;height:100%;">
              <div style="flex:1;background:var(--rule);border-radius:2px 2px 0 0;"></div>
              <div style="height:83%;background:var(--accent);opacity:1;"></div>
            </div>

          </div>
        </div>

        <!-- X labels -->
        <div style="display:flex;gap:10px;padding:10px 0 16px;padding-left:36px;">
          <div class="bar-lbl">2019<strong>59%</strong></div>
          <div class="bar-lbl">2020<strong>62%</strong></div>
          <div class="bar-lbl">2021<strong>55%</strong></div>
          <div class="bar-lbl">2022<strong>70%</strong></div>
          <div class="bar-lbl">H1 2023<strong>83%</strong></div>
        </div>

        <!-- Legend -->
        <div style="display:flex;gap:20px;padding-bottom:16px;padding-left:36px;">
          <div style="display:flex;align-items:center;gap:6px;font-size:11px;color:var(--muted);">
            <div style="width:12px;height:12px;background:var(--accent);border-radius:2px;opacity:.9;flex-shrink:0;"></div>
            Phase 3 or commercial-stage (de-risked)
          </div>
          <div style="display:flex;align-items:center;gap:6px;font-size:11px;color:var(--muted);">
            <div style="width:12px;height:12px;background:var(--rule);border-radius:2px;flex-shrink:0;"></div>
            Preclinical / early-stage
          </div>
        </div>

        <p class="chart-source">Source: IQVIA. Share of biopharma M&amp;A transactions (majority-stake, &gt;$1B) focused on de-risked targets with assets in Phase 3 or on market. The single most important factor in acquisition premium is the quality and differentiation of clinical data (Vision Lifesciences, 2025). Companies "built to buy" — with clean data, organized regulatory dossiers, and clear IP — close deals faster and at higher premiums.</p>
      </div>
    </div>
  </div>
</section>

  <!-- CONTACT -->
  <section id="contact">
    <div class="row">
      <div class="label">Contact</div>
      <div>
        <p class="contact-tag">Let's talk about where your program is and what it needs to get to the next inflection point.</p>
       <div class="contact-links">
  <a class="contact-link" href="mailto:amanda.gentile@gmail.com">Email Amanda <span class="arr">&#8594;</span></a>
  <a class="contact-link" href="tel:+16176459160">Call Amanda <span class="arr">&#8594;</span></a>
</div>
        </div>
        <p class="contact-note">First call covers program stage, near-term goals, key deliverables, and timeline. A simple statement of work follows. No long procurement cycles.</p>
      </div>
    </div>
  </section>

  <footer>
    <img class="footer-logo" src="CPCC_logo.png" alt="Cape Porpoise Clinical Consulting" />
    <div class="footer-meta">
      <p>&#169; <span id="y"></span> Cape Porpoise Clinical Consulting</p>
      <p>Cambridge, Massachusetts</p>
    </div>
  </footer>

  <script>document.getElementById("y").textContent = new Date().getFullYear();</script>
</body>
</html>
